| Literature DB >> 27156049 |
Domokos Máthé1, Krisztián Szigeti2, Nikolett Hegedűs3, Ildikó Horváth4, Dániel S Veres5, Béla Kovács6, Zoltán Szűcs7.
Abstract
(212)Pb is a clinically relevant therapeutic alpha emitter isotope. A surrogate, (203)Pb, if prepared with sufficiently high specific activity could be used to estimate (212)Pb in vivo absorbed doses. An improved production procedure of (203)Pb with a simple, new separation method and high specific radioactivity for imaging is reported. We determined the in-vivo biodistribution of (203)Pb in mice by SPECT/CT. This highlights application possibilities of (203)Pb for further in vivo and clinical uses (radiolabeled (212)Pb-peptide co-injection, dosimetry calculation).Entities:
Keywords: (203)Pb; (212)Pb; Gamma-emitting isotope; NanoSPECT/CT; Targeted alpha therapy
Mesh:
Substances:
Year: 2016 PMID: 27156049 DOI: 10.1016/j.apradiso.2016.04.015
Source DB: PubMed Journal: Appl Radiat Isot ISSN: 0969-8043 Impact factor: 1.513